REFERENCES
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-49.
2. Islami F, Baeker Bispo J, Lee H, et al. American cancer society’s report on the status of cancer disparities in the United States, 2023. CA Cancer J Clin. 2024;74:136-66.
3. Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32:605-44.
4. Samet JM, Avila-Tang E, Boffetta P, et al. Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin Cancer Res. 2009;15:5626-45.
5. Ramalingam SS, Yang JC, Lee CK, et al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J Clin Oncol. 2018;36:841-9.
6. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. Engl J Med. 2010;363:1693-703.
7. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005;23:857-65.
8. Tan AC, Tan DSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol. 2022;40:611-25.
9. Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14:531-48.
10. Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17:223-38.
11. Zhang P, Samuel G, Crow J, Godwin AK, Zeng Y. Molecular assessment of circulating exosomes toward liquid biopsy diagnosis of Ewing sarcoma family of tumors. Transl Res. 2018;201:136-53.
13. Bakouny Z, Hawley JE, Choueiri TK, et al. COVID-19 and cancer: current challenges and perspectives. Cancer Cell. 2020;38:629-46.
14. Richards M, Anderson M, Carter P, Ebert BL, Mossialos E. The impact of the COVID-19 pandemic on cancer care. Nat Cancer. 2020;1:565-7.
15. Spicer J, Chamberlain C, Papa S. Provision of cancer care during the COVID-19 pandemic. Nat Rev Clin Oncol. 2020;17:329-31.
16. Dutta A, Banerjee N, Chaudhuri M, Chatterjee S. Nucleic acid in diagnostics. In: Chatterjee S, Chattopadhyay S, Editors. Nucleic acid biology and its application in human diseases. Singapore: Springer Nature; 2023. pp. 213-69.
17. Serratì S, De Summa S, Pilato B, et al. Next-generation sequencing: advances and applications in cancer diagnosis. Onco Targets Ther. 2016;9:7355-65.
18. de Las Heras B, Saini KS, Boyle F, et al. Cancer treatment and research during the COVID-19 pandemic: experience of the first 6 months. Oncol Ther. 2020;8:171-82.
19. Rucinska M, Nawrocki S. COVID-19 pandemic: impact on cancer patients. Int J Environ Res Public Health. 2022;19:12470.
20. Katsuda T, Kosaka N, Ochiya T. The roles of extracellular vesicles in cancer biology: toward the development of novel cancer biomarkers. Proteomics. 2014;14:412-25.
21. Möller A, Lobb RJ. The evolving translational potential of small extracellular vesicles in cancer. Nat Rev Cancer. 2020;20:697-709.
22. Wang L, Wang G, Mao W, et al. Bioinspired engineering of fusogen and targeting moiety equipped nanovesicles. Nat Commun. 2023;14:3366.
23. Jumeaux C, Wahlsten O, Block S, et al. MicroRNA detection by DNA-mediated liposome fusion. Chembiochem. 2018;19:434-8.
24. Rahman MM, Abosheasha MA, Ito Y, Ueda M. DNA-induced fusion between lipid domains of peptide-lipid hybrid vesicles. Chem Commun. 2022;58:11799-802.
25. Ellison G, Zhu G, Moulis A, Dearden S, Speake G, McCormack R. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol. 2013;66:79-89.
26. Malapelle U, Sirera R, Jantus-Lewintre E, et al. Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer. Expert Rev Mol Diagn. 2017;17:209-15.
27. Ariyasu R, Uchibori K, Ninomiya H, et al. Feasibility of next-generation sequencing test for patients with advanced NSCLC in clinical practice. Thorac Cancer. 2021;12:504-11.
28. Zheng Z, Liebers M, Zhelyazkova B, et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat Med. 2014;20:1479-84.
29. Kaminski MM, Abudayyeh OO, Gootenberg JS, Zhang F, Collins JJ. CRISPR-based diagnostics. Nat Biomed Eng. 2021;5:643-56.
30. Ning B, Huang Z, Youngquist BM, et al. Liposome-mediated detection of SARS-CoV-2 RNA-positive extracellular vesicles in plasma. Nat Nanotechnol. 2021;16:1039-44.
31. Zheng Q, Ding H, Wang L, et al. Circulating exosomal miR-96 as a novel biomarker for radioresistant non-small-cell lung cancer. J Oncol. 2021;2021:5893981.
